The p53 inhibitor pifithrin-α can stimulate fibrosis in a rat model of ischemic acute kidney injury

American Journal of Physiology - Renal Physiology

Volumn 302, Issue 2, 2012, Pages

  Dagher, Pierre C ^a   Mai, Erik M ^a   Hato, Takashi ^a   Lee, So Young ^b   Anderson, Melissa D ^a   Karozos, Stephanie C ^a   Mang, Henry E ^a   Knipe, Nicole L ^a   Plotkin, Zoya ^a   Sutton, Timothy A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Eulji University   (South Korea)

Author keywords

Chronic; Fibronectin; Inflammation; Renal failure

Indexed keywords

CALVASCULIN; CD68 ANTIGEN; CREATININE; FIBRONECTIN; PIFITHRIN ALPHA; PROTEIN P53; SODIUM;

ACUTE KIDNEY FAILURE; ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; INFLAMMATION; KIDNEY FIBROSIS; KIDNEY ISCHEMIA; KIDNEY TUBULE CELL; MACROPHAGE; MALE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL ARTERY; REPERFUSION; SHAM PROCEDURE; SODIUM URINE LEVEL; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84855297121     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00317.2011     Document Type: Article

References (54)

1. Amdur RL, Chawla LS, Amodeo S, Kimmel PL, Palant CE. Outcomes following diagnosis of acute renal failure in U.S. veterans: focus on acute tubular necrosis. Kidney Int 76: 1089-1097, 2009.
2. Basile DP. Transforming growth factor-beta as a target for treatment in diabetic nephropathy. Am J Kidney Dis 38: 887-892, 2001.
3. Basile DP, Donohoe D, Roethe K, Osborn JL. Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am J Physiol Renal Physiol 281: F887-F899, 2001.
4. Basile DP, Donohoe DL, Roethe K, Mattson DL. Chronic renal hypoxia after acute ischemic injury: effects of L-arginine on hypoxia and secondary damage. Am J Physiol Renal Physiol 284: F338-F348, 2003.
5. Bluyssen HA, Lolkema MP, van Beest M, Boone M, Snijckers CM, Los M, Gebbink MF, Braam B, Holstege FC, Giles RH, Voest EE. Fibronectin is a hypoxia-independent target of the tumor suppressor VHL. FEBS Lett 556: 137-142, 2004.
6. Calzada MJ, Esteban MA, Feijoo-Cuaresma M, Castellanos MC, Naranjo-Suarez S, Temes E, Mendez F, Yanez-Mo M, Ohh M, Landazuri MO. von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxiainducible factor-independent mechanisms. Cancer Res 66: 1553-1560, 2006.
7. Charron AJ, Xu W, Bacallao RL, Wandinger-Ness A. Cablin: a novel protein of the capillary basal lamina. Am J Physiol Heart Circ Physiol 277: H1985-H1996, 1999.
8. Cummings MC. Increased p53 mRNA expression in liver and kidney apoptosis. Biochim Biophys Acta 1315: 100-104, 1996.
9. Dixon AJ, Burns J, Dunnill MS, McGee JO. Distribution of fibronectin in normal and diseased human kidneys. J Clin Pathol 33: 1021-1028, 1980.
10. Duffield JS. Macrophages and immunologic inflammation of the kidney. Semin Nephrol 30: 234-254, 2010.
11. Eckardt KU, Rosenberger C, Jurgensen JS, Wiesener MS. Role of hypoxia in the pathogenesis of renal disease. Blood Purif 21: 253-257, 2003.
12. Fine LG, Bandyopadhay D, Norman JT. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int Suppl 75: S22-S26, 2000.
13. Forbes JM, Hewitson TD, Becker GJ, Jones CL. Ischemic acute renal failure: long-term histology of cell and matrix changes in the rat. Kidney Int 57: 2375-2385, 2000.
14. Higgins DF, Biju MP, Akai Y, Wutz A, Johnson RS, Haase VH. Hypoxic induction of CTGF is directly mediated by HIF-1. Am J Physiol Renal Physiol 287: F1223-F1232, 2004.
15. Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B, Saito Y, Johnson RS, Kretzler M, Cohen CD, Eckardt KU, Iwano M, Haase VH. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 117: 3810-3820, 2007.
16. Hoagland MS, Hoagland EM, Swanson HI. The p53 inhibitor pifithrinalpha is a potent agonist of the aryl hydrocarbon receptor. J Pharmacol Exp Ther 314: 603-610, 2005.
17. Holness CL, Simmons DL. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood 81: 1607-1613, 1993.
18. Horbelt M, Lee SY, Mang HE, Knipe NL, Sado Y, Kribben A, Sutton TA. Acute and chronic microvascular alterations in a mouse model of ischemic acute kidney injury. Am J Physiol Renal Physiol 293: F688-F695, 2007.
19. Hoste EA, Schurgers M. Epidemiology of acute kidney injury: how big is the problem? Crit Care Med 36: S146-S151, 2008.
20. Ishani A, Xue JL, Himmelfarb J, Eggers PW, Kimmel PL, Molitoris BA, Collins AJ. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 20: 223-228, 2009.
21. Jiang M, Yi X, Hsu S, Wang CY, Dong Z. Role of p53 in cisplatininduced tubular cell apoptosis: dependence on p53 transcriptional activity. Am J Physiol Renal Physiol 287: F1140-F1147, 2004.
22. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112: 1776-1784, 2003.
23. Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, Schreiner GF, Johnson RJ. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 13: 806-816, 2002.
24. Kelly KJ, Plotkin Z, Vulgamott SL, Dagher PC. P53 mediates the apoptotic response to GTP depletion after renal ischemia-reperfusion: protective role of a p53 inhibitor. J Am Soc Nephrol 14: 128-138, 2003.
25. Kelly KJ, Sutton TA, Weathered N, Ray N, Caldwell EJ, Plotkin Z, Dagher PC. Minocycline inhibits apoptosis and inflammation in a rat model of ischemic renal injury. Am J Physiol Renal Physiol 287: F760-F766, 2004.
26. Knapp W, Dorken B, Rieber P, Schmidt RE, Stein H, von dem Borne AE. CD antigens 1989. Blood 74: 1448-1450, 1989.
27. Komarova EA, Neznanov N, Komarov PG, Chernov MV, Wang K, Gudkov AV. p53 inhibitor pifithrin alpha can suppress heat shock and glucocorticoid signaling pathways. J Biol Chem 278: 15465-15468, 2003.
28. Kurban G, Hudon V, Duplan E, Ohh M, Pause A. Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res 66: 1313-1319, 2006.
29. Lee SY, Horbelt M, Mang HE, Knipe NL, Bacallao RL, Sado Y, Sutton TA. MMP-9 gene deletion mitigates microvascular loss in a model of ischemic acute kidney injury. Am J Physiol Renal Physiol 301: F101-F109, 2011.
30. Liu G, Park YJ, Tsuruta Y, Lorne E, Abraham E. p53 Attenuates lipopolysaccharide-induced NF-kappaB activation and acute lung injury. J Immunol 182: 5063-5071, 2009.
31. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 15: 1-12, 2004.
32. Lo LJ, Go AS, Chertow GM, McCulloch CE, Fan D, Ordonez JD, Hsu CY. Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int 76: 893-899, 2009.
33. Mitchell RA, Liao H, Chesney J, Fingerle-Rowson G, Baugh J, David J, Bucala R. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA 99: 345-350, 2002.
34. Molitoris BA, Dagher PC, Sandoval RM, Campos SB, Ashush H, Fridman E, Brafman A, Faerman A, Atkinson SJ, Thompson JD, Kalinski H, Skaliter R, Erlich S, Feinstein E. siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol 20: 1754-1764, 2009.
35. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 17: 17-25, 2006.
36. Prakash J, de Borst MH, Lacombe M, Opdam F, Klok PA, van Goor H, Meijer DK, Moolenaar F, Poelstra K, Kok RJ. Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injury. J Am Soc Nephrol 19: 2086-2097, 2008.
37. Russell RC, Ohh M. NEDD8 acts as a "molecular switch" defining the functional selectivity of VHL. EMBO Rep 9: 486-491, 2008.
38. Sharfuddin AA, Molitoris BA. Pathophysiology of ischemic acute kidney injury. Nat Rev Nephrol 7: 189-200, 2011.
39. Sohn D, Graupner V, Neise D, Essmann F, Schulze-Osthoff K, Janicke RU. Pifithrin-alpha protects against DNA damage-induced apoptosis downstream of mitochondria independent of p53. Cell Death Differ 16: 869-878, 2009.
40. Stickle NH, Chung J, Klco JM, Hill RP, Kaelin WG Jr, Ohh M. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol Cell Biol 24: 3251-3261, 2004.
41. Strutz F, Okada H, Lo CW, Danoff T, Carone RL, Tomaszewski JE, Neilson EG. Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 130: 393-405, 1995.
42. Sutton TA, Wilkinson J, Mang HE, Knipe NL, Plotkin Z, Hosein M, Zak K, Wittenborn J, Dagher PC. p53 regulates renal expression of HIF-1 α and pVHL under physiological conditions and after ischemiareperfusion injury. Am J Physiol Renal Physiol 295: F1666-F1677, 2008.
43. Tang N, Mack F, Haase VH, Simon MC, Johnson RS. pVHL function is essential for endothelial extracellular matrix deposition. Mol Cell Biol 26: 2519-2530, 2006.
44. Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, D'Amelio M, Criollo A, Morselli E, Zhu C, Harper F, Nannmark U, Samara C, Pinton P, Vicencio JM, Carnuccio R, Moll UM, Madeo F, Paterlini-Brechot P, Rizzuto R, Szabadkai G, Pierron G, Blomgren K, Tavernarakis N, Codogno P, Cecconi F, Kroemer G. Regulation of autophagy by cytoplasmic p53. Nat Cell Biol 10: 676-687, 2008.
45. Van Vliet A, Baelde HJ, Vleming LJ, de Heer E, Bruijn JA. Distribution of fibronectin isoforms in human renal disease. J Pathol 193: 256-262, 2001.
46. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 137: 413-431, 2009.
47. Waikar SS, Liu KD, Chertow GM. Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol 3: 844-861, 2008.
48. Wald R, Quinn RR, Luo J, Li P, Scales DC, Mamdani MM, Ray JG. Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA 302: 1179-1185, 2009.
49. Wei Q, Dong G, Yang T, Megyesi J, Price PM, Dong Z. Activation and involvement of p53 in cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol 293: F1282-F1291, 2007.
50. Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 16: 535-543, 2010.
51. Yuan HT, Li XZ, Pitera JE, Long DA, Woolf AS. Peritubular capillary loss after mouse acute nephrotoxicity correlates with downregulation of vascular endothelial growth factor-A and hypoxia-inducible factor-1 alpha. Am J Pathol 163: 2289-2301, 2003.
52. Zhou L, Fu P, Huang XR, Liu F, Lai KN, Lan HY. Activation of p53 promotes renal injury in acute aristolochic acid nephropathy. J Am Soc Nephrol 21: 31-41, 2010.
53. Zuk A, Bonventre JV, Brown D, Matlin KS. Polarity, integrin, and extracellular matrix dynamics in the postischemic rat kidney. Am J Physiol Cell Physiol 275: C711-C731, 1998.
54. Zuk A, Bonventre JV, Matlin KS. Expression of fibronectin splice variants in the postischemic rat kidney. Am J Physiol Renal Physiol 280: F1037-F1053, 2001.